Synergy for nosocomial pneumonia due to Pseudomonas aeruginosa

Nosocomial pneumonia due to *Pseudomonas aeruginosa* is a severe lower respiratory tract infection, encompassing hospital-acquired and ventilator-associated pneumonia, caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa* Primarily affecting hospitalized patients—particularly critically ill individuals in intensive care units or those receiving mechanical ventilation—it is pathophysiologically characterized by microaspiration of colonized pathogens, extensive pulmonary pare...

Nosocomial pneumonia due to *Pseudomonas aeruginosa* is a severe lower respiratory tract infection, encompassing hospital-acquired and ventilator-associated pneumonia, caused by the opportunistic Gram-negative pathogen *Pseudomonas aeruginosa* Primarily affecting hospitalized patients—particularly critically ill individuals in intensive care units or those receiving mechanical ventilation—it is pathophysiologically characterized by microaspiration of colonized pathogens, extensive pulmonary pare...

Primarily affecting hospitalized patients—particularly critically ill individuals in intensive care units or those receiving mechanical ventilation—it is pathophysiologically characterized by microaspiration of colonized pathogens, extensive pulmonary parenchymal inflammation, epithelial necrosis, and impaired alveolar gas exchange

In this context, antimicrobial synergy denotes a pharmacodynamic strategy where combined therapeutic agents provide bactericidal activity exceeding their additive effects, frequently employed to overcome intrinsic or acquired multidrug resistance mechanisms, suppress resistant sub-clones, and optimize pulmonary bacterial clearance

In this context, antimicrobial synergy denotes a pharmacodynamic strategy where combined therapeutic agents provide bactericidal activity exceeding their additive effects, frequently employed to overcome intrinsic or acquired multidrug resistance mechanisms, suppress resistant sub-clones, and optimize pulmonary bacterial clearance

In this context, antimicrobial synergy denotes a pharmacodynamic strategy where combined therapeutic agents provide bactericidal activity exceeding their additive effects, frequently employed to overcome intrinsic or acquired multidrug resistance mechanisms, suppress resistant sub-clones, and optimize pulmonary bacterial clearance